Business Segments · Gain from cost and equity method investments
Oncology & Multispecialty — Gain from cost and equity method investments
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityVolatile
First reportedQ3 2025
Last reportedQ3 2025
How to read this metric
An increase reflects successful investment performance or divestitures, while a decrease suggests lower returns or lack of investment activity.
Detailed definition
The realized financial gains recognized by the Oncology and Multispecialty segment from its minority interests in other...
Peer comparison
Comparable to 'Investment Income' or 'Gains from Equity Method Investments' reported by diversified healthcare corporations.
Metric ID:
mck_segment_oncology_multispecialty_gain_from_cost_and_equity_method_investmentsHistorical Data
1 periods
| Q3 '25 | |
|---|---|
| Value | $51.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's oncology & multispecialty — gain from cost and equity method investments?
- McKesson (MCK) reported oncology & multispecialty — gain from cost and equity method investments of $51.00M in Q3 2025.
- What does oncology & multispecialty — gain from cost and equity method investments mean?
- Profits earned by the Oncology and Multispecialty segment from its investments in other companies.